Loading clinical trials...
Loading clinical trials...
The purpose of this study is to: * evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers * evaluate the effica...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Alnylam Pharmaceuticals
NCT06259292 · Hereditary Hemorrhagic Telangiectasia, Arteriovenous Malformations, and more
NCT07445347 · Hereditary Hemorrhagic Telangiectasia (HHT), Pulmonary Hypertension, and more
NCT04404881 · Hereditary Hemorrhagic Telangiectasia
NCT04874558 · Hereditary Hemorrhagic Telangiectasia
NCT07101575 · Hereditary Hemorrhagic Telangiectasia
Clinical Trial Site
Birmingham, Alabama
Clinical Trial Site
Cypress, California
Clinical Trial Site
Gainesville, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions